Nasser K Altorki

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9644778/publications.pdf

Version: 2024-02-01

160 papers	15,478 citations	46918 47 h-index	18075 120 g-index
165 all docs	165 docs citations	165 times ranked	16623 citing authors

#	Article	IF	Citations
1	Sublobar resection is comparable to lobectomy for screen-detected lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 1907-1915.	0.4	26
2	Outcomes After Surgical Resection of Early-stage Lung Adenocarcinomas With Epidermal Growth Factor Receptor Mutations. Annals of Thoracic Surgery, 2022, 114, 905-910.	0.7	3
3	Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report. Clinical Lung Cancer, 2022, 23, e238-e242.	1.1	14
4	Commentary: Surgery for ground-glass nodules: Free lunch or slippery slope?. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 465-466.	0.4	1
5	Minimally Invasive Surgery for Lung Cancer Following Neoadjuvant Therapy in the United States. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2022, , .	0.5	1
6	Adjuvant therapy for early-stage nonâ€“small cell lung cancer: The breaking of a new dawn. Journal of Thoracic and Cardiovascular Surgery, 2022, , .	0.4	1
7	Extent of Resection Influences Survival in Early-Stage Lung Cancer With Occult Nodal Disease. Annals of Thoracic Surgery, 2022, , .	0.7	7
8	Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in nonâ€“small cell lung cancer. Science Translational Medicine, 2022, 14, eabe8195.	5.8	16
9	Safety of lung cancer surgery during COVID-19 in a pandemic epicenter. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 378-385.	0.4	8
10	Integrative network analysis of early-stage lung adenocarcinoma identifies aurora kinase inhibition as interceptor of invasion and progression. Nature Communications, 2022, 13, 1592.	5.8	16
11	Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma. Cell Reports, 2022, 39, 110639.	2.9	15
12	Treatment of cT3N1M0/IIIA nonâ€“small cell lung cancer and the risk of underuse of surgery. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 256-263.e1.	0.4	2
13	Commentary: Can machine learning reduce readmissions after esophagectomy? A consummation devoutly to be wished. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 1944-1945.	0.4	1
14	52350 PKM2 mediates anti-tumor immunity and T cell dysfunction. Journal of Clinical and Translational Science, 2021, 5, 89-89.	0.3	0
15	Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC).. Journal of Clinical Oncology, 2021, 39, 4005-4005.	0.8	18
16	Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncology, The, 2021, 22, 824-835.	5.1	191
17	Two-field lymph node dissection or three-field lymph node dissection. What's in a name?. Journal of Thoracic and Cardiovascular Surgery, 2021, , .	0.4	3
18	Validation of a Circulating Tumor <scp>DNA</scp>-Based <scp>Next-Generation</scp> Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. Oncologist, 2021, 26, e1971-e1981.	1.9	11

#	Article	IF	Citations
19	Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer. Nature Cancer, 2021, 2, 919-931.	5.7	26
20	Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IBâ€“IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet, The, 2021, 398, 1344-1357.	6.3	689
21	Commentary: High-dose induction chemoradiation for lung cancer: The past is prologue. Journal of Thoracic and Cardiovascular Surgery, 2020, 160, 1346-1347.	0.4	0
22	Differential Contributions of Pre- and Post-EMT Tumor Cells in Breast Cancer Metastasis. Cancer Research, 2020, 80, 163-169.	0.4	62
23	Sternal Reconstruction Using Customized 3D-Printed Titanium Implants. Annals of Thoracic Surgery, 2020, 109, e411-e414.	0.7	17
24	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nature Medicine, 2020, 26, 1114-1124.	15.2	216
25	Commentary: Where is the leak? From the anastomosis or the database?. Journal of Thoracic and Cardiovascular Surgery, 2020, 160, 1096-1097.	0.4	0
26	Staple Line Thickening After Sublobar Resection: Reaction or Recurrence?. Annals of Thoracic Surgery, 2020, 109, 1670-1676.	0.7	6
27	Commentary: Lobectomy or sublobar resection for early lung cancer: One small step for surgeons, one giant step for patients. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 909-910.	0.4	2
28	Do the surgical results in the National Lung Screening Trial reflect modern thoracic surgical practice?. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 2038-2046.e1.	0.4	21
29	TOX is a critical regulator of tumour-specific T cell differentiation. Nature, 2019, 571, 270-274.	13.7	697
30	Adjuvant Therapy for Node-Positive Esophageal Cancer After Induction and Surgery: A Multisite Study. Annals of Thoracic Surgery, 2019, 108, 828-836.	0.7	28
31	Sublobar resection for node-negative lung cancer 2â€“5 cm in size. European Journal of Cardio-thoracic Surgery, 2019, 56, 858-866.	0.6	18
32	Role of wedge resection in bronchial carcinoid (BC) tumors: SEER database analysis. Journal of Thoracic Disease, 2019, 11, 1355-1362.	0.6	10
33	Reintervention and Survival After Limited Lung Resection for Lung Cancer Treatment in Australia. Annals of Thoracic Surgery, 2019, 107, 1507-1514.	0.7	3
34	Extent of lymphadenectomy is associated with oncological efficacy of sublobar resection for lung cancer â‰¤2Âcm. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 2454-2465.e1.	0.4	38
35	Do individual surgeon volumes affect outcomes in thoracic surgery?â€. European Journal of Cardio-thoracic Surgery, 2019, 56, 770-777.	0.6	16
36	Segmentectomy Is Equivalent to Lobectomy in Hypermetabolic Clinical Stage IA Lung Adenocarcinomas. Annals of Thoracic Surgery, 2019, 107, 217-223.	0.7	25

#	Article	IF	Citations
37	The lung microenvironment: an important regulator of tumour growth and metastasis. Nature Reviews Cancer, 2019, 19, 9-31.	12.8	692
38	Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology. Annals of Thoracic Surgery, 2019, 107, 187-193.	0.7	9
39	Molecular Testing for Early Lung Cancer. Archives of Pathology and Laboratory Medicine, 2018, 142, 794-795.	1.2	1
40	Predictors of Survival After Treatment of Oligometastases After Esophagectomy. Annals of Thoracic Surgery, 2018, 105, 357-362.	0.7	32
41	Are minimum volume standards appropriate for lung and esophageal surgery?. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2683-2694.e1.	0.4	29
42	T1N0 oesophageal cancer: patterns of care and outcomes over 25 yearsâ€. European Journal of Cardio-thoracic Surgery, 2018, 53, 952-959.	0.6	11
43	Pulmonary sarcomatoid carcinoma: an analysis of a rare cancer from the Surveillance, Epidemiology, and End Results databaseâ€. European Journal of Cardio-thoracic Surgery, 2018, 53, 828-834.	0.6	46
44	Never smokers with resected lung cancer: different demographics, similar survivalâ€. European Journal of Cardio-thoracic Surgery, 2018, 53, 842-848.	0.6	19
45	Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival. JCI Insight, 2018, 3, .	2.3	49
46	What is the role of wedge resection for T1a lung cancer?. Journal of Thoracic Disease, 2018, 10, S1157-S1162.	0.6	8
47	Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respiratory Medicine,the, 2018, 6, 915-924.	5.2	268
48	Consequences of Refusing Surgery for Esophageal Cancer: A National Cancer Database Analysis. Annals of Thoracic Surgery, 2018, 106, 1476-1483.	0.7	33
49	Incidence and Prognostic Significance of Carcinoid Lymph Node Metastases. Annals of Thoracic Surgery, 2018, 106, 981-988.	0.7	41
50	Lung cancer patients have the highest malignancy-associated suicide rate in USA: a population-based analysis. Ecancermedicalscience, 2018, 12, 859.	0.6	45
51	The importance of lymph node dissection accompanying wedge resection for clinical stage IA lung cancerâ€. European Journal of Cardio-thoracic Surgery, 2017, 51, ezw343.	0.6	28
52	Matrix Metalloproteinase 14 promotes lung cancer by cleavage of Heparin-Binding EGF-like Growth Factor. Neoplasia, 2017, 19, 55-64.	2.3	45
53	Robotic Thymectomy: Learning Curve and Associated Perioperative Outcomes. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2017, 27, 685-690.	0.5	24
54	Localizing small nodules: Is it time for a randomized trial?. Journal of Thoracic and Cardiovascular Surgery, 2017, 153, 1591.	0.4	0

#	Article	IF	Citations
55	The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein. Journal of Cell Biology, 2017, 216, 641-656.	2.3	35
56	Invited Commentary. Annals of Thoracic Surgery, 2017, 103, 421.	0.7	0
57	Biopsy first: Lessons learned from Cancer and Leukemia Group B (CALGB) 140503. Journal of Thoracic and Cardiovascular Surgery, 2017, 153, 1592-1597.	0.4	64
58	Video-Assisted Thoracoscopic Lobectomy Is the Preferred Approach Following Induction Chemotherapy. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2017, 27, 495-500.	0.5	33
59	Robotic Thymectomy Is Feasible for Large Thymomas: A Propensity-Matched Comparison. Annals of Thoracic Surgery, 2017, 104, 1673-1678.	0.7	46
60	Fischer et al. reply. Nature, 2017, 547, E5-E6.	13.7	21
61	Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response. Clinical Cancer Research, 2017, 23, 2673-2680.	3.2	49
62	What is the role of neoadjuvant chemotherapy, radiation, and adjuvant treatment in resectable esophageal cancer?. Annals of Cardiothoracic Surgery, 2017, 6, 167-174.	0.6	23
63	Distinct Akt phosphorylation states are required for insulin regulated Glut4 and Glut1-mediated glucose uptake. ELife, 2017, 6, .	2.8	121
64	The NeoRes trial: questioning the benefit of radiation therapy as part of neoadjuvant therapy for esophageal adenocarcinoma. Journal of Thoracic Disease, 2017, 9, 3465-3468.	0.6	4
65	A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010.. Journal of Clinical Oncology, 2017, 35, TPS8576-TPS8576.	0.8	4
66	Adenovirus Protein E4-ORF1 Activation of PI3 Kinase Reveals Differential Regulation of Downstream Effector Pathways in Adipocytes. Cell Reports, 2016, 17, 3305-3318.	2.9	13
67	Variability in length of stay after uncomplicated pulmonary lobectomy: is length of stay a quality metric or a patient metric?. European Journal of Cardio-thoracic Surgery, 2016, 49, e65-e71.	0.6	42
68	Incidence and implications of postoperative supraventricular tachycardia after pulmonary lobectomy. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 982-989.	0.4	21
69	Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 822-835.	5.1	390
70	Surgery is the Optimum Local Therapeutic Modality for Second Primary Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery, 2016, 28, 201-202.	0.4	0
71	Predictors of Pleural Implants in Patients WithÂThymic Tumors. Annals of Thoracic Surgery, 2016, 102, 1647-1652.	0.7	7
72	Anatomical Segmentectomy and Wedge Resections Are Associated with Comparable Outcomes for Patients with Small cT1N0 Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1984-1992.	0.5	108

#	Article	IF	Citations
73	Screening for Lung Cancer. Surgical Oncology Clinics of North America, 2016, 25, 469-479.	0.6	13
74	Lobectomy for Non-Small Cell Lung Cancer byÂVideo-Assisted Thoracic Surgery: Effects ofÂCumulative Institutional Experience on Adequacy of Lymphadenectomy. Annals of Thoracic Surgery, 2016, 101, 1116-1122.	0.7	47
75	Locally advanced esophageal cancer: What becomes of 5-year survivors?. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 726-732.	0.4	18
76	Video-Assisted Thoracoscopic Surgery Is a Safe and Effective Alternative to Thoracotomy for Anatomical Segmentectomy in Patients With Clinical Stage I Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2016, 101, 465-472.	0.7	85
77	Preoperative Chemoradiation Therapy Versus Chemotherapy in Patients Undergoing Modified En Bloc Esophagectomy for Locally Advanced Esophageal Adenocarcinoma: Is Radiotherapy Beneficial?. Annals of Thoracic Surgery, 2016, 101, 1262-1270.	0.7	33
78	The Microenvironment of Lung Cancer and Therapeutic Implications. Advances in Experimental Medicine and Biology, 2016, 890, 75-110.	0.8	96
79	Incidence and Factors Associated With Hospital Readmission After Pulmonary Lobectomy. Annals of Thoracic Surgery, 2016, 101, 434-443.	0.7	28
80	Predictors of Disease-free Survival and Recurrence in Patients with Resected Bronchial Carcinoid Tumors. Thoracic and Cardiovascular Surgeon, 2016, 64, 159-165.	0.4	14
81	Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma. Oncotarget, 2016, 7, 39957-39969.	0.8	49
82	Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC. PLoS ONE, 2015, 10, e0129123.	1.1	17
83	Sternal Resections: New Materials for Reconstruction. Current Surgery Reports, 2015, 3, 1.	0.4	7
84	Lung inflammation promotes metastasis through neutrophil protease-mediated degradation of Tsp-1. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 16000-16005.	3.3	168
85	Clinical predictors of early cancer-related mortality following neoadjuvant therapy and oesophagectomyâ€. European Journal of Cardio-thoracic Surgery, 2015, 48, 455-460.	0.6	19
86	Transcriptome Analysis of Individual Stromal Cell Populations Identifies Stroma-Tumor Crosstalk in Mouse Lung Cancer Model. Cell Reports, 2015, 10, 1187-1201.	2.9	137
87	Computed Tomography Screening. Thoracic Surgery Clinics, 2015, 25, 129-143.	0.4	11
88	Perioperative Outcomes after Lung Resection in Obese Patients. Thoracic and Cardiovascular Surgeon, 2015, 63, 544-550.	0.4	9
89	Reply. Annals of Thoracic Surgery, 2015, 99, 1865-1866.	0.7	2
90	Invited Commentary. Annals of Thoracic Surgery, 2015, 100, 286-287.	0.7	0

#	Article	IF	Citations
91	Invited Commentary. Annals of Thoracic Surgery, 2015, 99, 1893.	0.7	0
92	Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature, 2015, 527, 472-476.	13.7	1,498
93	Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 19-24.	0.4	19
94	Outcomes in the management of esophageal cancer. Journal of Surgical Oncology, 2014, 110, 599-610.	0.8	68
95	The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) Response to the USPSTF Recommendations. Journal of Thoracic Oncology, 2014, 9, 141-143.	0.5	23
96	Balancing curability and unnecessary surgery in the context ofÂcomputed tomography screening for lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1619-1626.	0.4	56
97	The Society of Thoracic Surgeons Practice Guidelines on the Role of Multimodality Treatment for Cancer of the Esophagus and Gastroesophageal Junction. Annals of Thoracic Surgery, 2014, 98, 1880-1885.	0.7	54
98	A Propensity-Matched Analysis of Wedge ResectionÂand Stereotactic Body Radiotherapy forÂEarly Stage Lung Cancer. Annals of Thoracic Surgery, 2014, 98, 1152-1159.	0.7	47
99	Surgical Lung Biopsy in Adult Respiratory Distress Syndrome: A Meta-Analysis. Annals of Thoracic Surgery, 2014, 98, 1254-1260.	0.7	46
100	Invited Commentary. Annals of Thoracic Surgery, 2014, 97, 288-289.	0.7	0
101	Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 754-764.	0.4	287
102	Invited Commentary. Annals of Thoracic Surgery, 2014, 97, 1981-1982.	0.7	0
103	Implementing lung cancer screening: a checklist. Lung Cancer Management, 2014, 3, 1-4.	1.5	4
104	Oesophageal Procedures. , 2014, , 193-201.		0
105	Ratio of Positron Emission Tomography Uptake to Tumor Size in Surgically Resected Nonâ€“Small Cell Lung Cancer. Annals of Thoracic Surgery, 2013, 95, 397-404.	0.7	27
106	Invited Commentary. Annals of Thoracic Surgery, 2013, 96, 1941-1942.	0.7	0
107	Invited Commentary. Annals of Thoracic Surgery, 2013, 96, 1195.	0.7	0
108	Long-Term Survival After Lobectomy for Non-Small Cell Lung Cancer by Video-Assisted Thoracic Surgery Versus Thoracotomy. Annals of Thoracic Surgery, 2013, 96, 951-961.	0.7	130

#	Article	IF	Citations
109	Outcomes after lobectomy using thoracoscopy vs thoracotomy: a comparative effectiveness analysis utilizing the Nationwide Inpatient Sample database. European Journal of Cardio-thoracic Surgery, 2013, 43, 813-817.	0.6	198
110	Thymic carcinoma: A cohort study of prognostic factors after surgical resection from the European Society of Thoracic Surgeons database.. Journal of Clinical Oncology, 2013, 31, 7602-7602.	0.8	0
111	Worldwide Oesophageal Cancer Collaboration guidelines for lymphadenectomy predict survival following neoadjuvant therapy. European Journal of Cardio-thoracic Surgery, 2012, 42, 659-664.	0.6	49
112	Definitive Therapy for Isolated Esophageal Metastases Prolongs Survival. Annals of Thoracic Surgery, 2012, 94, 413-420.	0.7	10
113	Preoperative Taxane-Based Chemotherapy and Celecoxib for Carcinoma of the Esophagus and Gastroesophageal Junction: Results of a Phase 2 Trial. Journal of Thoracic Oncology, 2011, 6, 1121-1127.	0.5	21
114	Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma. Journal of Thoracic and Cardiovascular Surgery, 2011, 141, 1196-1206.	0.4	50
115	Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease. Annals of Thoracic Surgery, 2011, 92, 491-498.	0.7	83
116	Lobectomy in Octogenarians With Non-Small Cell Lung Cancer: Ramifications of Increasing Life Expectancy and the Benefits of Minimally Invasive Surgery. Annals of Thoracic Surgery, 2011, 92, 1951-1957.	0.7	101
117	Analysis of Spontaneous Vs. Vaccine-Induced Antibody Responses Against Cancer-Testis Antigen MAGE-A3 in Cancer Patients. Blood, 2011, 118, 5087-5087.	0.6	0
118	Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: A propensity-matched analysis from the STS database. Journal of Thoracic and Cardiovascular Surgery, 2010, 139, 366-378.	0.4	721
119	Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer. Journal of Thoracic and Cardiovascular Surgery, 2010, 139, 387-394.	0.4	23
120	Predictors of Cervical and Recurrent Laryngeal Lymph Node Metastases From Esophageal Cancer. Annals of Thoracic Surgery, 2010, 90, 1805-1811.	0.7	25
121	Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 3131-3137.	0.8	136
122	Kaplan et al. reply. Nature, 2009, 461, E5-E5.	13.7	2
123	Invited Commentary. Annals of Thoracic Surgery, 2009, 87, 1065.	0.7	0
124	Predictors of Long-Term Survival After Resection of Esophageal Carcinoma With Nonregional Nodal Metastases. Annals of Thoracic Surgery, 2009, 88, 186-193.	0.7	46
125	Total Number of Resected Lymph Nodes Predicts Survival in Esophageal Cancer. Annals of Surgery, 2008, 248, 221-226.	2.1	242
126	Multifocal Neoplasia and Nodal Metastases in T1 Esophageal Carcinoma. Annals of Surgery, 2008, 247, 434-439.	2.1	81

#	Article	IF	Citations
127	Predicting Systemic Disease in Patients With Esophageal Cancer After Esophagectomy. Annals of Surgery, 2008, 248, 979-985.	2.1	279
128	PRIMARY SURGERY FOR ADENOCARCINOMA OF THE ESOPHAGUS. , 2008, , 486-491.		0
129	THREE-FIELD LYMPH NODE DISSECTION FOR CANCER OF THE ESOPHAGUS. , 2008, , 608-612.		0
130	Lymph Node Dissection for Carcinoma of the Esophagus. , 2007, , 225-233.		1
131	Downstaging of T or N Predicts Long-Term Survival After Preoperative Chemotherapy and Radical Resection for Esophageal Carcinoma. Annals of Thoracic Surgery, 2006, 82, 480-485.	0.7	46
132	Chemotherapy Induces the Expression of Cyclooxygenase-2 in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 4191-4197.	3.2	64
133	Bronchioloalveolar Carcinoma in Small Pulmonary Nodules: Clinical Relevance. Seminars in Thoracic and Cardiovascular Surgery, 2005, 17, 123-127.	0.4	7
134	En-bloc Esophagectomyâ€”The Three-Field Dissection. Surgical Clinics of North America, 2005, 85, 611-619.	0.5	29
135	Bronchioloalveolar Carcinoma and Ground Glass Opacities. Annals of Thoracic Surgery, 2005, 80, 1560-1561.	0.7	3
136	Imaging for Esophageal Tumors. Radiologic Clinics of North America, 2005, 43, 611-619.	0.9	1
137	COX-2 inhibition in upper aerodigestive tract tumors. Seminars in Oncology, 2004, 31, 30-35.	0.8	66
138	Imaging for esophageal tumors. Thoracic Surgery Clinics, 2004, 14, 61-69.	0.4	30
139	COX-2: a target for prevention and treatment of esophageal cancer. Journal of Surgical Research, 2004, 117, 114-120.	0.8	26
140	Surgical Resection for Lung Cancer in the Octogenarian. Chest, 2004, 126, 733-738.	0.4	120
141	Cyclooxygenase-2: A Target for the Prevention and Treatment of Cancers of the Upper Digestive Tract. , 2003, 37, 107-123.		3
142	Three-Field Lymph Node Dissection for Squamous Cell and Adenocarcinoma of the Esophagus. Annals of Surgery, 2002, 236, 177-183.	2.1	377
143	Diagnosis and management of early lung cancer. Surgical Clinics of North America, 2002, 82, 457-476.	0.5	7
144	Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: Evidence for involvement of bile acids. Gastroenterology, 2001, 121, 1391-1399.	0.6	134

#	Article	IF	Citations
145	Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncology, The, 2001, 2, 544-551.	5.1	481
146	Should En Bloc Esophagectomy Be the Standard of Care for Esophageal Carcinoma?. Annals of Surgery, 2001, 234, 581-587.	2.1	199
147	Early Lung Cancer Action Project. Cancer, 2001, 92, 153-159.	2.0	450
148	Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. International Journal of Cancer, 2001, 92, 856-860.	2.3	310
149	Early Lung Cancer Action Project. Annals of the New York Academy of Sciences, 2001, 952, 124-134.	1.8	47
150	Early Lung Cancer Action Project: A Summary of the Findings on Baseline Screening. Oncologist, 2001, 6, 147-152.	1.9	127
151	The Rationale for Radical Resection. Surgical Oncology Clinics of North America, 1999, 8, 295-305.	0.6	14
152	Inhibition of Cyclooxygenase-2 Gene Expression by p53. Journal of Biological Chemistry, 1999, 274, 10911-10915.	1.6	293
153	Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet, The, 1999, 354, 99-105.	6.3	2,359
154	Dihydroxy Bile Acids Activate the Transcription of Cyclooxygenase-2. Journal of Biological Chemistry, 1998, 273, 2424-2428.	1.6	178
155	En bloc esophagectomy improves survival for stage III esophageal cancer. Journal of Thoracic and Cardiovascular Surgery, 1997, 114, 948-956.	0.4	142
156	Occult cervical nodal metastasis in esophageal cancer: Preliminary results of three-field lymphadenectomy. Journal of Thoracic and Cardiovascular Surgery, 1997, 113, 540-544.	0.4	139
157	The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. International Journal of Cancer, 1995, 64, 37-46.	2.3	86
158	Defining the invasive phenotype of proximal gastric cancer cells. Cancer, 1994, 73, 22-27.	2.0	32
159	Characterization of cell lines established from human gastric-esophageal adenocarcinomas: Biologic phenotype and invasion potential. Cancer, 1993, 72, 649-657.	2.0	49
160	Signal transduction in tumor angiogenesis. , 0, , 861-871.		0